First human trial launches for potential cardiometabolic treatment
NCT ID NCT06336005
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new medicine, NNC6022-0001, for the first time in humans. It aims to check the drug's safety, how the body processes it, and how it works. Healthy adults aged 18-55 will receive either a single dose of the drug or a placebo. The results will help decide if further testing in patients is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC6022-0001
- What this could lead to
- If successful, this could pave the way for a new treatment option for cardiometabolic diseases like heart disease or diabetes.
- What could go wrong
- This is a very early, small study in healthy volunteers, so it may not show the hoped-for effects or could reveal safety issues. Many early-stage drugs do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMETABOLIC DISEASES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON - location Groningen
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults